|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Archrock Partners, L.P. New York, April 03, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Archrock Partners, L.P. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest quality, and lowest cost cannabis cultivators in the world.PharmaCielo (TSXV: PCLO) (OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical ...
Moody's Investors Service, (Moody's) assigned a B2 rating to Archrock Partners, L.P.'s (Archrock) proposed $400 million senior unsecured notes issue due 2028. The notes are being co-issued by Archrock Partners Finance Corp., a wholly-owned subsidiary of Archrock. Proceeds from the offering will be used to repay borrowings under the company's revolving credit facility and general corporate purposes.